Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Apatinib 5 days' continuous use and 2 days' off | Experimental | Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer |
|
| Apatinib 500mg continuous use | Active Comparator | Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Apatinib | Drug | Apatinib 500mg with Docetaxel 60mg/m2 |
|
| Measure | Description | Time Frame |
|---|---|---|
| progress free survival(PFS) | From data of randomization until the date of first dccumentde progression or date of death from any cause | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| disease control rate (DCR) | investigators will assess treatment response according to Response Evaluation Criteria in Soid Tumor | 1year |
| Objective tumor response rate(ORR) | difined as the percentage of subjects having achieved confirmed Complete Response+Partial Response as best overall response according to radiological assessments |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| yifu He, doctor | Contact | 0551-65327666 | 834638033@qq.com |
| Name | Affiliation | Role |
|---|---|---|
| yifu He, doctor | Anhui Provincial Cancer Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anhui Provincial Cancer Hospital | Recruiting | Hefei | Anhui | 230000 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35280426 | Derived | Yan Y, Li H, Wu S, Wang G, Luo H, Niu J, Cao L, Hu X, Xu H, Jia W, Sun Y, Yao Y, Chen W, Ke L, Hu B, Ji C, Sun Y, Chen J, Li M, He Y. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study. Ann Transl Med. 2022 Feb;10(4):205. doi: 10.21037/atm-22-546. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C553458 | apatinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1year |
| overall survival (os) | difined as the length of time from random assignment to death or to last contact | 1year |
| Quality of life score | a questionnaire developed to assess the quality of life of cancer patients | 1 year |
| adverse events | adverse events are evaluated according to National Cancer institute Common Terminology Criteria for Adverse Events | 1 year |